about
Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.Optimizing the management of children with latent tuberculosis infection.Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of three protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner.TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical DevelopmentThe current status, challenges, and future developments of new tuberculosis vaccines.Development of New Preventive and Therapeutic Vaccines for Tuberculosis.
P2860
Q30403003-A7203CD6-6885-4BF6-A6EE-F02520BB6226Q39079240-3CBE2AAB-7F9E-466C-BD59-BD4923D89754Q41995267-A9C125F3-D5CE-4C89-9668-AB1147F59551Q41996136-FD19DC91-C5F6-405E-81A9-3DF55C091AAEQ42372774-1EEBE5FD-7E77-4351-8426-DBBFD2C9E740Q52337140-54D366CB-1A0B-4177-90EA-5DB986DE6A0EQ55280574-98133B1F-70AA-40F0-B717-FA896D22D397
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Towards new TB vaccines: What are the challenges?
@en
type
label
Towards new TB vaccines: What are the challenges?
@en
prefLabel
Towards new TB vaccines: What are the challenges?
@en
P2860
P356
P1476
Towards new TB vaccines: What are the challenges?
@en
P2860
P304
P356
10.1093/FEMSPD/FTW016
P577
2016-03-09T00:00:00Z